Thermosome Presents Encouraging Initial Clinical Data from Phase I Trial of Lead Compound THE001
19. November 2024 04:00 ET
|
AKAMPION
THE001 safe and well tolerated in first two dose level, demonstrating encouraging signs of clinical activityData presented at The Connective Tissue Oncology Society (CTOS) Annual Meeting 2024 Munich,...
Ebenbuild Appoints Charles A. Taylor, PhD as Chairman of the Board
11. November 2024 04:00 ET
|
AKAMPION
World renowned researcher and leader in predictive, simulation-based medicine to support further growth and strengthen footprint in the U.S. Munich, Germany, November 11, 2024 -- Ebenbuild, a company...
ANEUVO präsentiert wegweisendes Neuromodulationssystem ExaStim® auf der MEDICA 2024
06. November 2024 04:00 ET
|
AKAMPION
Neuartiges Produkt mit FDA Breakthrough Device Designation zur Behandlung chronischer RückenmarksverletzungenTechnologie wird in Halle 10 / H44 vorgestellt Düsseldorf, Deutschland – 6....
AMYRA Successfully Demonstrates a New Therapeutic Paradigm for Gluten-Related Disorders in a First-in-Human Study
23. Oktober 2024 04:00 ET
|
AKAMPION
Lead product AMYNOPEP achieves proof-of-principle in exploratory clinical studyAMYNOPEP is the first and only gluten-digesting enzyme combination that supports and enhances the activity of critical...
Preliminary Data of BellaSeno’s Clinical Trial on Scaffold-Guided Breast Regeneration Presented at the 93rd Annual Plastic Surgery Meeting in San Diego, CA
09. Oktober 2024 04:00 ET
|
AKAMPION
Performance: Statistically significant superiority over fat grafting, with breast volume retention twice as highSafety: BellaSeno’s scaffolds are safe and improve patient satisfaction and well-being ...
Mabylon AG Receives Research Grants Totaling More Than CHF 1.3 Million for Amyotrophic Lateral Sclerosis (ALS) and Inflammasome Programs
24. September 2024 04:00 ET
|
AKAMPION
Schlieren, Zurich/Switzerland, September 24, 2024 - Mabylon AG, a leader in the high-throughput discovery, characterization, and development of human-derived antibodies, today announced that it has...
ImmunOs Therapeutics AG Raises $11 Million and Further Strengthens Investor Base
17. September 2024 04:00 ET
|
AKAMPION
Existing investors and new investor Double Point Ventures join forces to support ImmunOs TherapeuticsInvestment secures funding of ongoing promising clinical trial of IOS-1002 in solid cancers ...
ImmunOs Therapeutics Expands Phase I Clinical Trial of IOS-1002 in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Solid Tumors
24. Juli 2024 04:00 ET
|
AKAMPION
Dosing of patients in new combination treatment arm – IOS-1002 plus KEYTRUDA Schlieren (Zurich Area), Switzerland – July 24, 2024 – ImmunOs Therapeutics AG, a biopharmaceutical company using its...
BellaSeno Reports Positive Interim Findings of Australian Clinical Trials in Breast Scaffold Patients
12. Juni 2024 04:00 ET
|
AKAMPION
Favorable safety profile of resorbable breast scaffolds in one-year follow-upNo major scaffold-related complications or scaffold removals BellaSeno will initiate multicenter pivotal clinical trial...
Thermosome Appoints Dr. Sabine Hauck as Chief Technical Officer
11. Juni 2024 04:00 ET
|
AKAMPION
- Experienced biopharma professional focused on drug product development Munich, Germany - June 11, 2024 - Thermosome, a drug development company focused on targeted tumor therapies, today...